• Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line).
  
• Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (PubMed=8423216; PubMed=14522906).
  

PubMed=2551628; DOI=10.1210/endo-125-4-1783
Pang X.-P., Hershman J.M., Chung M., Pekary A.E.
Characterization of tumor necrosis factor-alpha receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin.
Endocrinology 125:1783-1788(1989)

PubMed=8423216; DOI=10.1172/JCI116168; PMCID=PMC330012
Fagin J.A., Matsuo K., Karmakar A., Chen D.-L., Tang S.-H., Koeffler H.P.
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
J. Clin. Invest. 91:179-184(1993)

PubMed=8871538; DOI=10.1007/BF00128960
Boghaert E.R., Ain K.B., Taylor K.D., Greenberg V.L., Fowler C., Zimmer S.G. Sr.
Quantitative and qualitative differences in growth, invasion and lung colonization of an anaplastic and a papillary human thyroid cancer cell line in vitro and in vivo.
Clin. Exp. Metastasis 14:440-450(1996)

PubMed=11439348; DOI=10.1038/sj.onc.1204531
Frasca F., Vigneri P., Vella V., Vigneri R., Wang J.Y.-J.
Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to hepatocyte growth factor.
Oncogene 20:3845-3856(2001)

PubMed=14522906
Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R., Vigneri P.
p73 tumor-suppressor activity is impaired in human thyroid cancer.
Cancer Res. 63:5829-5837(2003)

PubMed=15980887; DOI=10.1038/labinvest.3700306
Nakamura N., Carney J.A., Jin L., Kajita S., Pallares J., Zhang H.-Y., Qian X., Sebo T.J., Erickson L.A., Lloyd R.V.
RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors.
Lab. Invest. 85:1065-1075(2005)

PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569
Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. 3rd, Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

PubMed=20143388; DOI=10.1002/ijc.25242
Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A., MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R., Freshney R.I.
Check your cultures! A list of cross-contaminated or misidentified cell lines.
Int. J. Cancer 127:1-8(2010)

PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690; PMCID=PMC3229662
Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
Clin. Cancer Res. 17:7248-7264(2011)